ReviewJACC. CardioOncology2019
AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.
Review in JACC. CardioOncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Changes in Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Patients Following Chemotherapy
Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis: Prognostic Significance
Who cites it
41 citing papers in PubMed, 69 citations in OpenAlex.
- Efficacy and Safety of Low-Frequency Daratumumab Regimen in Systemic Light-Chain Amyloidosis.Cancer medicine · 2026Article
- Left Bundle Branch Area Pacing versus Right Ventricular Pacing in Cardiac Amyloidosis: the Left-Right CA study, a single center, retrospective comparative non-randomized analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis.Annals of medicine · 2025Article
- Cardiac Amyloidosis: Tribulations and New Frontiers.Journal of personalized medicine · 2025Review
- What Cardiologists Should Know About Amyloidosis.Journal of clinical medicine · 2025Review
- Amyloid and Anderson-Fabry disease: Can there be a CMR phenotypic overlap?Journal of cardiology cases · 2025Article
- Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research.BMC health services research · 2025Article
- Thoracic Fat Pad Biopsy in Cardiac Amyloidosis: Diagnostic Yield in an Afro-Caribbean Population.Journal of clinical medicine · 2025Article
- The Prognostic Value of Platelet-to-Lymphocyte Ratio and Tricuspid Regurgitation Velocity in Patients with Light-Chain Myocardial Amyloidosis.Journal of inflammation research · 2025Article
- Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy.Frontiers in cardiovascular medicine · 2025Article
- Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.ESC heart failure · 2024Article
- Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review.Cureus · 2024Review
- Diagnostic value of left ventricular layer strain and specific regional strain patterns in cardiac amyloidosis and Fabry disease.European heart journal open · 2024Article
- Resolution of Cardiac Infiltration Following Autologous Stem Cell Transplantation for AL Amyloidosis.JACC. Case reports · 2024Article
- Appraisal of amyloidosis imaging practices in the Middle East/North Africa (PYP-MENA).European heart journal. Imaging methods and practice · 2024Article
- Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS.Frontiers in pharmacology · 2024Article
- Examining the Difficulties in Identifying and Handling Cardiac Amyloidosis; Acquiring Important Knowledge and Robust Treatment Methods.Cardiovascular & hematological disorders drug targets · 2024Review
- Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls.Internal and emergency medicine · 2023Review
- Article
- A Review of Current and Evolving Imaging Techniques in Cardiac Amyloidosis.Current treatment options in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AL amyloidosis results from clonal production of immunoglobulin light chains, most commonly arising from a clonal plasma cell disorder. Once considered a nearly uniformly fatal disease, prognosis has improved markedly over the past 15 years, predominantly because of advances in light chain suppressive therapies. Cardiac deposition of amyloid fibrils is common, and the severity of cardiac involvement remains the primary driver of prognosis. Improvements in chemotherapy/immunotherapy have prompted a reassessment of the role of advanced cardiac therapies previously considered contraindicated in most patients, including the role of implantable cardioverter-defibrillators and cardiac transplantation. This state-of-the-art review highlights the current state of the field, including diagnosis, prognosis, and hematologic- and cardiac-specific therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.